CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial
Document Type
Letter to the Editor
Publication Date
11-1-2020
Journal
American Heart Journal
Volume
229
DOI
10.1016/j.ahj.2020.07.017
APA Citation
Gutierrez, J., Heizer, G., Jones, W., Rockhold, F., Mahaffey, K., Fowkes, F., Berger, J., Baumgartner, I., Held, P., Katona, B., Norgren, L., Blomster, J., Hiatt, W., & Patel, M. (2020). CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. American Heart Journal, 229 (). http://dx.doi.org/10.1016/j.ahj.2020.07.017